Illumina · 9 hours ago
Associate Director, M&A Corporate Development (San Diego/Hybrid)
US - California - San Diego
Full-time
Hybrid
Lead/Staff, Director/Executive
$171K/yr - $256K/yr
15+ years expIllumina is a company focused on expanding access to genomic technology for health equity. The Associate Director, Corporate Development, will drive global growth through M&A, strategic partnerships, and new business creation, leading the full deal lifecycle and collaborating with executive leadership.
BiotechnologyGeneticsHealth CareMedical
Responsibilities
Lead and shape Illumina’s strategic opportunity pipeline by defining external growth strategy (build vs. buy vs. partner), priority spaces, unmet needs, and long-term growth themes. Establish clear investment theses, articulate where Illumina must play to win, and build forward-looking landscapes that integrate market trends, competitive dynamics, scientific innovation, and technology inflection points
Independently identify, source, and evaluate M&A and partnership opportunities across global markets. Conduct targeted assessments of companies and technologies—including competitive positioning, scientific and IP strength, commercial models, and financial implications—and translate insights into clear, actionable recommendations for senior executives
Independently lead transactions of varying scale and complexity. Develop investment theses, coordinate early-stage discussions, lead valuation, deal structuring, diligence planning and management, and complex deal structuring and negotiation, partner with Legal and Finance, and prepare executive- and board-level materials. Establish and drive diligence timelines, synthesize findings, identify risks, and develop mitigation plans. Provide clear, actionable conclusions to executive leadership. Act as a point of accountability for advancing deals through Illumina’s governance process
Partner with integration leaders to design integration strategies, operating models, and synergy plans for completed acquisitions. Support PMO execution through structured workstreams, governance cadence, KPI reporting, and risk management to ensure effective operational and financial value realization
Develop high-quality materials and analyses for the Executive Leadership Team (ELT), CEO, CFO, and Board of Directors. Communicate complex strategic, financial, and technical issues with clarity and authority. Influence decision-making across senior stakeholders
Qualification
Required
Typically requires a Bachelor's degree and a minimum of 15 years of related experience leading or significantly contributing to M&A transactions, including evaluation, diligence, negotiation, and integration, with 7+ years of Management experience, or an equivalent combination of experience and education
Demonstrated track record of independently driving deal analysis and cross-functional workstreams at a leading investment bank, private equity/venture firm, or corporate development team
Strong strategic thinking with the ability to translate scientific, commercial, and financial insights into actionable recommendations
Deep knowledge of the biotechnology, genomics, or diagnostics sectors, with familiarity across emerging technologies and competitive dynamics
Exceptional communication, executive presence, and stakeholder management skills, with the ability to partner effectively across senior leadership
Preferred
Global transaction experience strongly preferred
Benefits
Access to genomics sequencing
Family planning
Health/dental/vision
Retirement benefits
Paid time off
Company
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
5001-10000 employees
H1B Sponsorship
Illumina has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (134)
2024 (116)
2023 (159)
2022 (180)
2021 (123)
2020 (111)
Funding
Current Stage
Public CompanyTotal Funding
$1.28BKey Investors
Bank of America
2024-09-06Post Ipo Debt· $500M
2023-01-04Post Ipo Debt· $750M
2000-07-28IPO
Leadership Team
Steven Barnard
Chief Technology Officer, Head of Research & Product Development
Jenny Lei Zheng
SVP & GM of Greater China
Recent News
2026-01-22
2026-01-20
Company data provided by crunchbase